We recently compiled a list of the 13 Best Stocks to Invest In on Robinhood for Beginners. Revolution Medicines, Inc. is one of the best Robinhood stocks.

TheFly reported on March 16 that Jefferies initiated coverage of RVMD with a Buy rating and set a price target of $140, up from $88. The firm emphasized the potential of its RAS(ON) platform and positioned itself as a key innovation in oncology. According to Jefferies, the Phase 3 RASolute 302 trial is expected to accomplish its first interim endpoints, indicating a favorable path for the company’s clinical and commercial outlook. Daraxonrasib is recognized as having great possibilities to transform treatment for second-line pancreatic cancer.

Separately, Revolution Medicines, Inc. (NASDAQ:RVMD) declared on March 17 that it will provide important updates from its pipeline of RAS(ON) inhibitors at the 2026 American Association for Cancer Research (AACR) Annual Meeting, which is set for April 17–22 in San Diego.

New Phase 1 data for zoldonrasib in previously treated KRAS G12D mutant non-small cell lung cancer and Phase 1/2 results for daraxonrasib in first-line metastatic pancreatic ductal adenocarcinoma, both as monotherapy and in combination with chemotherapy, are among the nine oral and poster presentations the company has planned. Preclinical research on next-generation catalytic RAS(ON) inhibitors will be covered in other sessions, demonstrating the company’s extensive clinical and discovery efforts to target RAS-driven malignancies and overcome resistance.

Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical‑stage oncology company developing targeted therapies designed to address difficult‑to‑treat cancers driven by RAS/MAPK pathway mutations using precision‑focused small‑molecule inhibitors.

While we acknowledge the potential of RVMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.